Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
about
Advances and challenges in malaria vaccine developmentA review of malaria vaccine clinical projects based on the WHO rainbow tableThe evolution of poxvirus vaccinesMatrix and backstage: cellular substrates for viral vaccinesProtective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite proteinA phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in KenyaIdentification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profilingComparison of clinical and parasitological data from controlled human malaria infection trialsPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsNovel viral vectored vaccines for the prevention of influenza.Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens.Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responsesSuccessful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donorsCharacterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus.Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease.Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesThe influence of delivery vectors on HIV vaccine efficacySterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesTranslating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsA statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01EDNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsDifferent levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies.A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.The potential for a controlled human infection platform in Singapore.Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite densityEvaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals.Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cellsA human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.
P2860
Q21032463-18A78D23-9052-416F-A03A-FDBA78A3AE16Q21034112-F15D3E51-09A6-4C2B-8701-6602820F0067Q26995905-B4A54C6C-401E-44D1-AD72-699D64893DBEQ27025941-14D6B2D7-1673-47A0-9E68-C93FC686593BQ27310086-E7007FB2-9689-4646-95CC-9AE99469D374Q28469062-4E9BDA8C-99A9-463F-84D0-838D339AE0C3Q28704543-423FD8E1-98C6-4407-BEF5-433023B03D08Q28728616-2234A07E-29BA-40DF-9C66-88A48DC45A7AQ28731894-9A5B322F-48B0-4AE1-B1AE-F91F475744DBQ30418570-C4EE84F4-B6F0-44D5-89D4-23EC5F224611Q33294698-AF781190-539E-40CD-87B6-5010B233F8DDQ33303670-0BB81087-5144-4C5B-955A-8F105A26A2D9Q33317265-1BAC31F9-9990-4E01-A603-6D078B9D0AF8Q33557760-B1B315B9-59B8-4761-A603-8DEF5DD082AFQ33680757-37284A26-82A8-4B36-8A74-6C538DBF7372Q33725157-C9F653AB-0D3A-4255-A014-A9F8E14F0DB9Q33779750-36D59488-294D-483B-AD70-162BC33EE59EQ33821137-5B8C7877-B248-4CA2-BC19-792F20C679BAQ33855899-36167A03-9C29-43CE-8751-0B056ACC6A08Q33868760-D56A2934-8E6A-4E17-A586-B87B0CF41EC7Q33974904-5CABABAA-E39B-43FF-B68C-3477263D921BQ34055541-1E642A03-5C11-4E52-B59D-16F5BF9FDDE7Q34077543-126E3A0B-0494-41B6-8F6D-6146ED6EE9FAQ34165879-9ABCCC10-143A-4478-9723-B2495362A35BQ34301461-42664309-EBBB-4B44-AB76-9A9D9AFB8905Q34541330-7CB08C44-2380-4D10-A5E2-393392A4FCB9Q34606356-42E3717C-ECAF-4B9C-8CB3-C496284B1A2DQ34634002-E8FF863F-7F46-442A-A383-E91DC9590A32Q34720414-4901E437-E2A2-4774-BA5E-6E5D94D2628CQ34734075-4BA4FB05-7C02-4CE4-835C-B62ACABA7826Q34952265-DEA7ED5A-9B2F-461B-B63B-C9014410C4BFQ34983659-3E761393-912E-49A0-B1A0-027E8D0D6954Q35073970-66AC6FB3-E5DD-47A0-A234-D43217AFAADEQ35131085-3194B4D8-C3A7-4757-A90E-35ADFF727E29Q35163318-98CEB21A-D311-47A4-BF6E-5AAA32BF5FF2Q35217534-73BF8AEE-16E5-4AFC-B957-875EE0A227CDQ35292450-A3D1BCFA-6A2F-4EEB-9D45-7203EE237D45Q35367108-86A7F142-4E6D-4F38-AC3C-360EF3F1C4CBQ35561160-AB911716-56F9-44B1-85E3-66855A2206B6Q35571248-DEC51B90-1C2B-4331-A5CC-9521E6E85408
P2860
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Enhanced T cell-mediated prote ...... modified vaccinia virus Ankara
@ast
Enhanced T cell-mediated prote ...... modified vaccinia virus Ankara
@en
type
label
Enhanced T cell-mediated prote ...... modified vaccinia virus Ankara
@ast
Enhanced T cell-mediated prote ...... modified vaccinia virus Ankara
@en
prefLabel
Enhanced T cell-mediated prote ...... modified vaccinia virus Ankara
@ast
Enhanced T cell-mediated prote ...... modified vaccinia virus Ankara
@en
P2093
P2860
P50
P356
P1476
Enhanced T cell-mediated prote ...... modified vaccinia virus Ankara
@en
P2093
Daniel P Webster
Geoff Butcher
Ian Poulton
Jenni M Vuola
Laura Andrews
Rikke F Andersen
Robert Sinden
P2860
P304
P356
10.1073/PNAS.0406381102
P407
P50
P577
2005-03-21T00:00:00Z